

UNITED STATE DEPARTMENT OF COMMERCE **Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 09/012,272 01/23/98 LEE S 028870-080 **EXAMINER** 021839 HM12/0202 BURNS DOANE SWECKER & P 0 BOX 1404 ART UNIT PAPER NUMBER ALEXANDRIA VA 22313-1404

DATE MAILED:

02/02/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No.		
09/	0/2,	272

Office Action Summary

Applicant(s)

Lee et al.

Examiner

Group Art Unit

ı	Pak, J. 16/6
-The MAILING DATE of this communication appears on the	
Period for Reply	2
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPI OF THIS COMMUNICATION.	REMONTH(S) FROM THE MAILING DATE
 Extensions of time may be available under the provisions of 37 CFR 1.136(a). from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within If NO period for reply is specified above, such period shall, by default, expire S Failure to reply within the set or extended period for reply will, by statute, cause 	n the statutory minimum of thirty (30) days will be considered timely.
Status , ,	
Responsive to communication(s) filed on //19/2000	
☐ This action is FINAL .	
☐ Since this application is in condition for allowance except for for accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D.	
Disposition of Claims	
	is/are pending in the application.
Of the above claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
	is/are rejected.
□ Claim(s)	is/are objected to.
□ Claim(s)	
	requirement.
Application Papers	
Application Papers ☐ See the attached Notice of Draftsperson's Patent Drawing Revie	w, PTO-948.
☐ See the attached Notice of Draftsperson's Patent Drawing Revie	is □ approved □ disapproved.
☐ See the attached Notice of Draftsperson's Patent Drawing Revie ☐ The proposed drawing correction, filed on	is □ approved □ disapproved.
 □ See the attached Notice of Draftsperson's Patent Drawing Revie □ The proposed drawing correction, filed on	is □ approved □ disapproved.
 □ See the attached Notice of Draftsperson's Patent Drawing Revie □ The proposed drawing correction, filed on	is □ approved □ disapproved.
 □ The proposed drawing correction, filed on is/are objected to be The oath or declaration is objected to be the Examiner. Priority under 35 U.S.C. § 119 (a)-(d) □ Acknowledgment is made of a claim for foreign priority under 35 All Some* None of the CERTIFIED copies of the priority creceived. 	is approved disapproved. by the Examiner. U.S.C. § 11 9(a)-(d). brity documents have been
 □ See the attached Notice of Draftsperson's Patent Drawing Revie □ The proposed drawing correction, filed on	is approved disapproved. by the Examiner. U.S.C. § 11 9(a)-(d). brity documents have been
 □ See the attached Notice of Draftsperson's Patent Drawing Revie □ The proposed drawing correction, filed on	u.S.C. § 11 9(a)-(d). ority documents have been all Bureau (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drawing Revie □ The proposed drawing correction, filed on	u.S.C. § 11 9(a)-(d). ority documents have been all Bureau (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drawing Revies □ The proposed drawing correction, filed on	is approved disapproved. by the Examiner. U.S.C. § 11 9(a)-(d). brity documents have been all Bureau (PCT Rule 1 7.2(a)).
□ See the attached Notice of Draftsperson's Patent Drawing Revie □ The proposed drawing correction, filed on	is approved disapproved. by the Examiner. U.S.C. § 11 9(a)-(d). brity documents have been all Bureau (PCT Rule 1 7.2(a)).

Serial Number: 09/012,27

Art Unit: 1616

The request filed on 1/19/2000 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/012,272 is acceptable and a CPA has been established. An action on the CPA follows.

Claims 1-4 and 6-9 are pending in this application. No amendment has been filed in this CPA.

Claim 6 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In applicant's reply of 10/23/98, claim 6 is noted as "(amended)" but no amendatory change can be discerned. Further, applicant should end the claim with a period and denote the percentages as weight percentages. The subject matter of claim 6 is unclear to the extent that the amendatory changes cannot be understood. Applicant is advised that clarification of these matters and reintroduction of the claim in independent form, incorporating all of the limitations of claim 1 into claim 6, would result in an allowable claim.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Page 3

Serial Number: 09/012,27

Art Unit: 1616

Claims 1-4 and 7-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bonfield et al. in view of Shimono et al. for the reasons of record.

Applicant's arguments have been given due consideration, but were deemed unpersuasive. First, for the reasons of record, the Examiner maintains his position that (i) the inventive subject matter is still readable on incorporation of active anti-inflammatory agents into bioactive glass, and (ii) use of such anti-inflammatory active agent containing bioactive glass to provide skin inflammation treatment would have been obvious to the ordinary skilled artisan. The invention claimed, to the broad extent that it is readable, is therefore obvious within the meaning of section 103. Second, while applicant asserts "novel method of treating inflammation" with bioactive glass per se, his objective evidence of such novelty, and nonobviousness, is only directed to bioactive glass "4585". The independent claim 1 requires only SiO₂, CaO and P₂O₅. Note that this is the most rudimentary description of glass in general, and it does not even require the presence of Na₂O, which is present at 24.5 wt% in "4585." Plainly applicant's objective evidence of nonobviousness, if any, is not commensurate in scope with that of the claimed subject matter. In re Kulling, 14 USPQ2d 1056, 1058 (Fed. Cir. 1990); In re Lindner, 173 USPQ 356, 358 (CCPA 1972).

¹ It is noted that the makeup of "45S5" is recited in claim 6.

Art Unit: 1616

For these reasons, all claims must be refused. No claim is allowed at this time. This Action is being made non-final to afford applicant another opportunity to overcome the rejections of record.

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or (703) 305-3592.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Examiner Pak whose telephone number is (703) 308-4538. The Examiner can normally be reached on Monday through Thursday from 8:00 AM to 5:30 PM. The Examiner can also be reached on alternate Fridays. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. José Dees, can be reached on (703) 308-4628. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

JOHN PAK PRIMARY EXAMINER GROUP 1200